83.53 USD
▲+0.67+0.98%
盘后 85.00 +2.76%
2026-08-03
市值
$1.23B
市盈率
—
EPS
-8.39
股息率
—
52 周区间
20.55 – 155.29
成交量
217.68K
Beta
3.42
目标价
277.50
52W 低 20.5552W 高 155.29
价格走势
公司简介
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung canc...